Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study

Press/Media: Press / Media

PeriodApr 3 2017 → Apr 10 2017

Media coverage

19

Media coverage

  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date4/10/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletBioSpace
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletSPi World News
    CountryUnited Kingdom
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletNasdaq
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletYahoo! Finance
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletPM 360
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outlet4 Traders
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletTeleTrader.com
    CountryAustria
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletStockwatch
    CountryCanada
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletCustomer Zone 360.com
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletIndia Pharma News
    CountryIndia
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletPipelineReview
    CountrySpain
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletPharmacy Choice
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletGlobeNewswire
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletDaily Times Leader
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletBizWire Express
    CountryIndia
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletPrimeNewswire (Top News)
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning
  • TitleAmicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
    Media name/outletWorld News Report
    CountryUnited States
    Date4/3/17
    PersonsJohn C Browning